Followers | 46 |
Posts | 4523 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, September 13, 2021 11:23:22 AM
$3 netcash-per-share?
Takeda, going forward, to incur all research expenses?
Two Phase-3-commencement announcement catalysts upcoming in 2021?
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021. If successful, Takeda estimates that soticlestat could receive approval in its fiscal year 2023.
https://docoh.com/filing/1636651/0001564590-21-044455/OVID-8K/file/2
Recent OVID News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 12:03:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:02:49 PM
- Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:00:00 PM
- Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer • GlobeNewswire Inc. • 08/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 09:22:46 PM
- Ovid Therapeutics to Present at Upcoming August Investor Conferences • GlobeNewswire Inc. • 07/30/2024 12:00:00 PM
- Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 11:10:10 AM
- Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat • GlobeNewswire Inc. • 06/17/2024 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:22:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/14/2024 09:19:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 12:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 12:03:02 PM
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 12:00:00 PM
- Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/13/2024 11:00:00 AM
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/04/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 01:24:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:20:05 PM
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 11:00:45 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM